• A major U.S.-India trade agreement is among several deals in final stages, per White House economic advisor Kevin Hassett.
  • Market optimism grows as S&P 500 climbs 2.5% on trade deal expectations.
  • The recent U.S.-U.K. pact serves as a template for forthcoming agreements with India, Japan, and Switzerland.

Momentum Builds for Bilateral Trade Deals

White House National Economic Council Director Kevin Hassett confirmed that negotiations with India are "close to the finish line," following productive talks between Vice President JD Vance and Indian Prime Minister Narendra Modi. The administration views the recently finalized U.S.-U.K. trade agreement as a model for structuring upcoming pacts, with Japan and Switzerland also advancing toward deals.

Investors responded positively to the news, driving the S&P 500 up 2.5% as markets priced in reduced trade friction. "We're seeing real momentum across multiple fronts," Hassett said, though he declined to specify timelines. Treasury officials familiar with the negotiations noted that tariff structures and intellectual property protections remain key discussion points with India.

Sector-Specific Implications

While details remain undisclosed, analysts expect technology, pharmaceuticals, and advanced manufacturing to benefit disproportionately from any U.S.-India agreement. The administration's "onshoring" strategy—using tariffs to incentivize domestic production—could reshape supply chains for medical devices and semiconductors in particular.

One industry lobbyist, speaking anonymously due to ongoing negotiations, suggested automotive parts manufacturers are pushing for "clear rules of origin" provisions. Meanwhile, Indian generic drugmakers are reportedly seeking concessions on FDA approval processes.

Broader Economic Context

The push comes as Hassett projects U.S. GDP growth could exceed 4% in late 2025 if these deals materialize. With approximately two dozen trade negotiations in various stages globally, the administration appears focused on securing quick bilateral wins rather than complex multilateral agreements.

Update: This article has been revised to clarify that tariff discussions specifically involve medical devices and semiconductors, not broader technology exports.